{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"2"}],"title":"Progressive Disease"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"2"}],"units":"Participants"}],"description":"Objective response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10mm. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesion, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progressions). Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.","groups":[{"description":"Single agent intravenous (IV) mithramycin\n\nMithramycin: 30 mcg/kg intravenous (IV) over 6 hours once daily for 7 days, to be repeated every 21 days (one cycle) until disease progression or unacceptable toxicity.","id":"OG000","title":"Dose Level 1 - 30 mcg/kg Thoracic Malignancy"},{"description":"Single agent intravenous (IV) mithramycin\n\nMithramycin: 30 mcg/kg intravenous (IV) over 6 hours once daily for 7 days, to be repeated every 21 days (one cycle) until disease progression or unacceptable toxicity.","id":"OG001","title":"Dose Level 1 - 30 mcg/kg Extra Thoracic Malignancy"},{"description":"Single agent intravenous (IV) mithramycin\n\nMithramycin: 25 mcg/kg intravenous (IV) over 6 hours once daily for 7 days, to be repeated every 21 days (one cycle).","id":"OG002","title":"Dose Level -1 - 25 mcg/kg Thoracic Malignancy"},{"description":"Single agent intravenous (IV) mithramycin\n\nMithramycin: 25 mcg/kg intravenous (IV) over 6 hours once daily for 7 days, to be repeated every 21 days (one cycle).","id":"OG003","title":"Dose Level -1 - 25 mcg/kg Extra Thoracic Malignancy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"One participant in DL1 30 mcg thoracic died on study, one participant in DL1 30 mcg extra thoracic experienced a dose limiting toxicity and was taken off therapy, and 1 withdrew prior to trmt, two participants in DL1 25 mcg thoracic died on study, and two did not complete one course of therapy prior to treatment evaluation for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Every 8 weeks until disease progression or unacceptable toxicity, over an average of 4 months.","title":"Number of Participants With an Objective Response (Complete Response + Partial Response)","type":"PRIMARY","unitOfMeasure":"Participants"}